Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment

Lung Cancer Clinical Trial

— ALTAKRA-1405  

Official title:

Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02540174
• Other study ID #: ALTAKRA-1405
• Status: Completed
• Phase: N/A
• Start date: May 27, 2015
• Est. completion date: December 12, 2017

Study information

• Verified date: July 2019
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, interventional, randomized study among patients with a first lung or head & neck cancer who are still active smokers ± alcohol misusers.The study will aim to compare the systematic implementation of an addiction treatment program initiated at hospital and integrated to the initial cancer treatment program (Arm A), versus the as-usual procedure, which consists in recommendations to follow an addiction treatment program (Arm B)

Description:

• Study proposal at the first medical consultation for therapeutic management of a first upper aerodigestive tract cancer or lung cancer.

• Selection criteria validation

• Collection of an informed consent

• Randomization :

Arm A: Experimental arm : Addiction consultation to the overall cancer treatment

Arm B: standard of care

The completion of questionnaires , the measurement of exhaled carbone monoxide rate using a CO tester for all patients, and the integrated addiction treatment among patients randomized in Arm A will not interfere with the medical treatment of cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: December 12, 2017
• Est. primary completion date: November 9, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with a first upper aerodigestive tract cancer or a lung cancer

• Initial cancer treatment

• Aged = 18 and =65 years

• Living within a radius of 20 km from the CHRU de Lille/Oscar Lambret Center

• Patient with tobacco addiction: regular smoker = at least 7 cigarettes /week or 1 cigarette/day or short-term ex-smoker = regular smoker who has stopped smoking for less than 1 year from the inclusion date

• Performance status (ECOG/WHO) = 2

• Registered with a social security system

• Informed and signed consent collected before initiation of any study procedures

Exclusion Criteria:

• Previous lung cancer or upper aerodigestive tract cancer

• Previous other cancer < 5 years, evoluting or treated at the inclusion (except uterine cervical carcinoma, basal cell or squamous cell skin carcinoma )

• Mesothelioma and esophageal cancer

• Occasional smoker (less than 7 cigarettes/week or less than 1 cigarette/day)

• Long-term ex-smokers who have stopped smoking for more than 1 year from the inclusion date

• Impossibility to comply with the study procedures due to geographic, social or mental reasons

• Patient under guardianship or tutorship

• Pregnant or breastfeeding women

Related Conditions & MeSH terms

• Behavior, Addictive
• Head and Neck Neoplasms
• Lung Cancer
• Lung Neoplasms
• Upper Aerodigestive Tract Neoplasms

Intervention

Procedure:
• integrated addiction treatment program
At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester. At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption. The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program.
• standard of care
The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology : At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester. At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption

Locations

Country	Name	City	State
France	CHRU of Lille : Albert Calmette Hospital	Lille
France	CHRU of Lille: Huriez Hospital	Lille
France	Oscar Lambret Center	Lille

Sponsors (3)

Lead Sponsor	Collaborator
Centre Oscar Lambret	Centre Régional de Référence en Cancérologie, National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in the rates of tobacco abstinent patients at 12 months between arms A and B	to be a "tobacco abstinent" patient has to : be a smoker at the inclusion (M0); declare to be weaned at M6; not declare a consumption between M6 and M12; a CO rate less than 10 ppm measured with a CO test at M6 and M12; We compare the two arms in term of tobacco abstinent patients rate.	1 year
Secondary	Frequency of alcohol and tobacco consumptions during the study	We considere the tobacco and alcohol consumption levels at T0, M3, M6, M12 by the consumption statement and the behaviour change towards tobacco and alcohol, thanks to questionnaires study specific.	initial diagnosis, after 3, 6 and 12 months
Secondary	Percentage of tobacco abstinent patients at 12 months	to be a "tobacco abstinent" patient has to : be a smoker at the inclusion (M0); declare to be weaned at M6; not declare a consumption between M6 and M12; a CO rate less than 10 ppm measured with a CO test at M6 and M12; We calculate the percentage of tobacco abstinent patients at 12 months considering every patient in the trial.	1 year
Secondary	Difference in the rates of alcohol and tobacco abstinent patients at 12 months depending on whether or not they have received an addiction treatment	We use a specialized monitoring in addictology (tobacco/alcohol) at 12 months according to the arms. The information of a monitoring in addictology will be obtained by the study specific questionnaire at M3, M6, M12	1 year
Secondary	Median time between inclusion date and the date of death (from any cause)	Time until progression. The time between the date of inclusion and the date of death whatever the cause is.	1 year
Secondary	Median progression-free time	delay between inclusion date and progression date (clinical or radiological)	1 year
Secondary	Percentage of Arm A patients who attended the addiction treatment program after the first systematic consultation	We note for each patient in arm A if they have at least one addictology specialized consultation after the first consultation which is imposed, during the 12 months	1 year